Page 630«..1020..629630631632..640650..»

Stem Cell Therapy For Parkinsons Disease | Stem Cell Malaysia – Video

By NEVAGiles23


Stem Cell Therapy For Parkinsons Disease | Stem Cell Malaysia
stemcellmalaysia.com Stem cell therapy for Parkinson #39;s Disease is still under research and study. However, there are impressive results by patients using oral placenta as stem cell therapy for their Parkinson #39;s disease. An 81 years old Asian with Stage 2 Parkinson #39;s disease observed cessation of tremor after only 4 weeks of oral placenta stem cell therapy. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:118 2ratingsTime:11:49More inScience Technology

Read the rest here:
Stem Cell Therapy For Parkinsons Disease | Stem Cell Malaysia - Video

To Read More: Stem Cell Therapy For Parkinsons Disease | Stem Cell Malaysia – Video
categoriaUncategorized commentoComments Off on Stem Cell Therapy For Parkinsons Disease | Stem Cell Malaysia – Video | dataNovember 21st, 2012
Read All

New technique to deliver stem cell therapy may help damaged eyes regain their sight – Video

By raymumme


New technique to deliver stem cell therapy may help damaged eyes regain their sight
Engineers at the University of Sheffield have developed a new technique for delivering stem cell therapy to the eye which they hope will help the natural repair of eyes damaged by accident or disease.From:ResearchatSheffieldViews:0 0ratingsTime:01:31More inScience Technology

Continue reading here:
New technique to deliver stem cell therapy may help damaged eyes regain their sight - Video

To Read More: New technique to deliver stem cell therapy may help damaged eyes regain their sight – Video
categoriaUncategorized commentoComments Off on New technique to deliver stem cell therapy may help damaged eyes regain their sight – Video | dataNovember 21st, 2012
Read All

NeoStem Receives Notification Of $1.2 million NIH Grant Award For First Clinical Study Of VSELTM Technology In Humans

By raymumme

NeoStem, Inc. (NYSE:NBS ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy industry, today announced that it has been awarded a two year grant totaling $1,221,854 for "Repair of Bone Defects with Human Autologous Pluripotent Very Small Embryonic-Like Stem Cells (VSEL)", grant number 2R44DE022493-02A1, from the National Institute of Dental and Craniofacial Research (NIDCR), a division of the National Institutes of Health (NIH). This peer reviewed grant is to support a Phase 2 investigation and first approved NIH clinical study of VSELsTM in humans. The study will be headed by Denis O. Rodgerson, Ph.D., Director of Grants and Academic Liaison for NeoStem, in collaboration with co-investigators Drs. Russell Taichman and Laurie McCauley of the University of Michigan. Enrollment for this study is expected to begin in 2013.

This award will fund the evaluation of VSELTM stem cells as a potential treatment for periodontitis. The product candidate, an autologous therapy derived from a patient's own stem cells, is to be developed for use in the regeneration of bone tissue damaged by this disease. The award includes $706,682 for the first year and $515,172 for the second year of the project, and will cover the cost of the Investigational New Drug (IND) submission to the FDA for the product candidate.

Dr. Denis O. Rodgerson, Director of Grants and Academic Liaison for NeoStem, said, "We are pleased and honored that NIH has agreed to support further studies on bone regeneration by using VSELTM stem cells. This is an extension of our successful NIH funded collaboration with Dr. Taichman showing the production of human bone from human VSELsTM in a mouse model."

Periodontal disease is prevalent in the U.S. and affects up to 90% of the world population. The most severe cases of periodontal disease affect between 5% and 15% of the U.S. population, or between 15 and 47 million Americans. The incidence of periodontal disease is estimated to be between 1 and 3 million Americans annually, and growing at a 7% rate each year. Studies have shown that periodontal inflammation could have a role in the initiation or progression of coronary heart disease and stroke. Market research experts have estimated that severe periodontal disease represents a market between $1.25 and $1.5 billion annually.

Dr. Russell Taichman, Major Ash Collegiate Professor and Co-Director of the Scholars Program in Dental Leadership, Department of Periodontics & Oral Medicine, University of Michigan stated, "I am thrilled for the possibilities that this award opens. The chance to continue to partner with NeoStem to further develop regenerative therapies is significant. The validation that this award brings and the opportunity to establish a proof of concept, which may impact human health, is truly rewarding." Dr. Laurie McCauley, The William K. and Mary Anne Najjar Professor, Division of Periodontics Department of Periodontics and Oral Medicine, University of Michigan added, "This novel cell based therapeutic approach looks to validate scientifically sound pre-clinical studies and provide a vital translation to improved human patient care."

NeoStem has a worldwide exclusive license to VSEL technology which uses very small embryonic-like stem cells, a heterogeneous population of stem cells found in adult bone marrow that have properties similar to those of embryonic stem cells. NeoStem has shown that very small embryonic-like stem cells can be mobilized into the peripheral blood, enabling a minimally invasive means for collecting what it believes to be an important population of stem cells that may have the potential to achieve the positive benefits associated with embryonic stem cells without the ethical or moral dilemmas or the potential negative biological effects associated with embryonic stem cells.

Dr. Robin L. Smith, Chairman and CEO of NeoStem, added, "We are very excited about this important step of funding for what will be the first human clinical study for our VSELTM technology. Not only will this study expand our knowledge of how autologous cell therapy can treat periodontitis and other bone defects, but it represents a milestone for NeoStem as we move our development of VSELTM technology beyond animal models and into the clinic, paving the way for other potential VSELTM trials."

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

Excerpt from:
NeoStem Receives Notification Of $1.2 million NIH Grant Award For First Clinical Study Of VSELTM Technology In Humans

To Read More: NeoStem Receives Notification Of $1.2 million NIH Grant Award For First Clinical Study Of VSELTM Technology In Humans
categoriaUncategorized commentoComments Off on NeoStem Receives Notification Of $1.2 million NIH Grant Award For First Clinical Study Of VSELTM Technology In Humans | dataNovember 21st, 2012
Read All

Stem cell therapy is immoral – bishop

By raymumme

MANILA, Philippines - A ranking official of the Catholic Bishops Conference of the Philippines (CBCP) considers immoral the embryonic stem cell therapy reportedly being used by politicians and actors for aesthetic purposes.

In an interview with Radio Veritas, CBCP-Episcopal Commission on Bioethics Chairman and Malolos Bishop Jose Oliveros said this medical procedure is against the belief of the Church. He said they are still assessing if the same could be said for stem cells from animals.

Pero yung sinasabi nila na pampabata sa mga politician at celebrities na sumailalim sa stem cell therapy ay immoral. Puwede namang ma-improve ang mukha ng isang tao, but it should be moral. Kapag gumamit ka ng immoral ay mali na yun, he said.

Embryo is still a maturing fetus.

He said the CBCP will come out with a pastoral statement regarding the matter once they are able to clarify certain matters with the Department of Health (DOH).

The DOH earlier warned people from using stem cells from aborted babies and human embryos.

The Philippine government will not allow the use of aborted fetuses or human embryosThere is a need to ensure that the biological raw materials are documented and validated and follow infection-free procedures, the DOH earlier said.

There is also a need to know if the materials to be injected came from animal or human tissues, it added.

Read the rest here:
Stem cell therapy is immoral - bishop

To Read More: Stem cell therapy is immoral – bishop
categoriaUncategorized commentoComments Off on Stem cell therapy is immoral – bishop | dataNovember 21st, 2012
Read All

Urologic Surgery Pioneer Dr. Alexander Gershman Joins Medistem's Scientific Advisory Board

By JoanneRUSSELL25

SAN DIEGO, CA--(Marketwire - Nov 19, 2012) - Medistem ( PINKSHEETS : MEDS ) announced today appointment of Alexander Gershman, MD, Ph.D to the company's Scientific Advisory Board.Dr. Gershman is an internationally-renowned opinion leader in urological surgery having pioneered numerous minimally invasive procedures using laparoscopic techniques.

"The future of regenerative medicine lies not only in having the best stem cell product, but also being able to practically deliver it in a manner that can be integrated into existing medical practice,"said Dr. Alan Lewis, CEO of Medistem. "Through working with respected physicians such as Dr. Gershman, our aim is to develop novel delivery methods so that our cellular product can be utilized in numerous disciplines."

Medistem is currently running a Phase II clinical trial in heart failure patients using its Endometrial Regenerative Cell (ERC) product delivered through a 30-minute minimally invasive patent pending procedure.The company seeks to develop similar minimally invasive procedures for the field of urology in collaboration with Dr. Gershman.

"It is obvious that stem cell medicine is the future of medicine.Although great strides have occurred in clinical entry of stem cells, a major hurdle to commercialization is practical implementation,"said Dr. Gershman. "I commend Medistem for having discovered what appears to be the most potent blood vessel generating stem cell, the ERC, as well as having the foresight to think practically about optimum methods of delivery."

Dr. Gershman is one of the first surgeons in the world to apply the method of laparoscopic surgery and robotic-assisted surgery to urology.He currently holds numerous hospital appointments, including the following: Director of Institute of Advanced Urology at the Cedars-Sinai Medical Center; Director of Urologic Laparoscopy in the Division of Urology, Harbor-UCLA Medical Center; Head of Endourology Division, Department of Surgery, VA Greater Los Angeles Healthcare System; Attending Surgeon, Laparoscopic Renal Transplant Surgery, St. Mary Medical Center; Attending Surgeon at the Cedars-Sinai Medical Center; and Attending Surgeon at the Harbor-UCLA Medical Center.

About Medistem Medistem Inc. is focused on the development of the Endometrial Regenerative Cell (ERC), a universal donor adult stem cell product. ERCs possess specialized abilities to stimulate new blood vessel growth and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. These unique properties have applications for treatment of critical limb ischemia (CLI), congestive heart failure (CHF), neurodegenerative diseases, liver failure, kidney failure, and diabetes. ERCs have been cleared by the FDA to begin studies in the United States.

ERCs have several distinguishing advantages to other stem cell therapies: a) Non-invasive method of collection; b) Unlimited supply of cells; isolated from menstrual blood of young healthy donors; c) Economical and scalable to manufacture; d) Exert higher therapeutic activity compared to other stem cells; and e) demonstrated safe in animal and pilot human studies.

Cautionary Statement This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

Read more here:
Urologic Surgery Pioneer Dr. Alexander Gershman Joins Medistem's Scientific Advisory Board

To Read More: Urologic Surgery Pioneer Dr. Alexander Gershman Joins Medistem's Scientific Advisory Board
categoriaUncategorized commentoComments Off on Urologic Surgery Pioneer Dr. Alexander Gershman Joins Medistem's Scientific Advisory Board | dataNovember 19th, 2012
Read All

Hair Loss PRP-Stem Cell Therapy-2 month comparison- Large.m4v – Video

By raymumme


Hair Loss PRP-Stem Cell Therapy-2 month comparison- Large.m4v
http://www.newininstitute.com.au PRP Therapy was chosen instead of a Hair Transplant to treat an area of hair loss in a female. 2 month comparison Before and After photos show a highly successful outcome. Note that continued hair growth will occur over the coming months. Another procedure will need to be performed at around the peak period: 12-18 months when growth begins to slow. Newin Institute has uniquely developed processes and protocols for PRP and Adipose Stem Cell Therapy.From:Rhett BosnichViews:0 0ratingsTime:00:55More inScience Technology

Here is the original post:
Hair Loss PRP-Stem Cell Therapy-2 month comparison- Large.m4v - Video

To Read More: Hair Loss PRP-Stem Cell Therapy-2 month comparison- Large.m4v – Video
categoriaUncategorized commentoComments Off on Hair Loss PRP-Stem Cell Therapy-2 month comparison- Large.m4v – Video | dataNovember 19th, 2012
Read All

What Are Stem Cells and Stem Cell Therapy Stemenhance – Video

By daniellenierenberg


What Are Stem Cells and Stem Cell Therapy Stemenhance
http://www.stemcellproduct.net This video gives you the definition, facts, and understanding on what are stem cells, that there are two of them embryonic and adult stem cells, how they work and the uses of stem cell when the tissue is affected in your body and how messengers signal the bone marrow to release adult stem cells to help in the repair of the injured tissue. Why this information is exciting for me to do a video is because I see stemcells as the best way of how to produce optimal health in your body. The way I look at it is that optimal health equals the number of healthy cells in your body and the only way the body repairs a damaged area is by creating and sending adult stem cells to that area. That #39;s why I #39;m introducing a stem cell product from a nutrition company who patented a stem cell enhancer which supports the release of adult stem cells. What will also excite you too is that Stemtech (the stemcell company) has also come out with two other products that will also optimize the circulation of these stem cells and other nutrients and aid in the ability for them to move and migrate into the affected tissue where they can transform and duplicate into fresh, healthy new cell tissue. So in my eyes having products like these will help anyone in my pursuit of health and wellness. I know it #39;s helping me strengthening my cells in my body after being diagnosed with chronic fatigue syndrome 20 plus years ago because I know how important nutrition and cell help to gain my ...From:Jennifer MarksViews:1 0ratingsTime:06:37More inHowto Style

View original post here:
What Are Stem Cells and Stem Cell Therapy Stemenhance - Video

To Read More: What Are Stem Cells and Stem Cell Therapy Stemenhance – Video
categoriaUncategorized commentoComments Off on What Are Stem Cells and Stem Cell Therapy Stemenhance – Video | dataNovember 19th, 2012
Read All

Bio-Matrix' Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate(TM) Cell Therapy

By NEVAGiles23

SAN DIEGO, CA--(Marketwire - Nov 19, 2012) - Bio-Matrix Scientific Group, Inc. ( OTCQB : BMSN ) announced today that its wholly owned subsidiary, Regen BioPharma, Inc., has contracted Cascade Life Sciences, Inc. to research the safety and efficacy of Regen's HemaXellerate product usingmice models for testing.Cascade Life Sciences is a privately-owned San Diego-based company with a platform of stem cell related technologies that are being advanced to serve the research community and the commercial development of stem cell-based therapeutics. Sophia Khaldoyanidi, M.D., Ph.D. is the principal investigator of the study.

The results of Regen's study will provide the safety profile data required for filing of anInvestigational New Drug (IND) application for the product with the US Food and Drug Administration .Regen intends to file an IND Application in the fourth quarter of 2012 and conduct Phase I/II clinical trials during 2013 and 2014.

HemaXellerate offers the possibility of delivering a population of endothelial cells to restore blood production in patients with hematological conditions."Unlike current approaches of administering pharmaceuticals," said J. Christopher Mizer, President of Regen BioPharma, "our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone marrow into producing blood cells naturally."

Regen has submitted two provisional patent applications covering the use of different sources of endothelial cells to heal damaged bone marrow. These applications cover: (1) placental cells (61/648898 - Acceleration 0f Hematopoietic Reconstitution by Placental Endothelial and Endothelial Progenitor Cells); and (2) fat cells (61/670791 - Treatment of Hematopoietic Disorders).

About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:

Bio-Matrix Scientific Group, Inc. ( OTCQB : BMSN ) is a biotechnology company developing regenerative medicine therapies. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications.

Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. ( OTCQB : BMSN ), is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. To follow our development, visit us at http://www.regenbiopharma.com.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks

View original post here:
Bio-Matrix' Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate(TM) Cell Therapy

To Read More: Bio-Matrix' Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate(TM) Cell Therapy
categoriaUncategorized commentoComments Off on Bio-Matrix' Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate(TM) Cell Therapy | dataNovember 19th, 2012
Read All

Scientists pushing Genetic engineering ahead despite strong opposition to GM … – Economic Times

By Dr. Matthew Watson


Economic Times
Scientists pushing Genetic engineering ahead despite strong opposition to GM ...
Economic Times
Siva Reddy of the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Delhi is developing a better way of using agricultural waste. He is engineering plant choloroplasts - the machinery that fixes sunlight - to make cellulase, an ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGFJE--Z0rDZDh91cIf9TtL93hgxg&url=http://economictimes.indiatimes.com/news/news-by-industry/et-cetera/scientists-pushing-genetic-engineering-ahead-despite-strong-opposition-to-gm-crops/articleshow/17187696.cms

To Read More: Scientists pushing Genetic engineering ahead despite strong opposition to GM … – Economic Times
categoriaUncategorized commentoComments Off on Scientists pushing Genetic engineering ahead despite strong opposition to GM … – Economic Times | dataNovember 18th, 2012
Read All

Biotechnology Spurs Talk At Food Dialogues – Farm Futures

By Dr. Matthew Watson


Farm Futures
Biotechnology Spurs Talk At Food Dialogues
Farm Futures
The third panel held at The Food Dialogues in New York City covered "Your Toughest Questions Answered on Biotechnology and Your Food." Moderated by Ali Velshi, CNN chief business correspondent, panelists included Dr. Bob Goldberg, plant molecular ...
Final Panel Thoughts from USFRA Food DialoguesAgWired
U.S. Farmers & Ranchers Alliance Names Nine Finalists For Its Faces Of ...Beef Magazine

all 38 news articles »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEAejAacXhY7hSeE8gfa4WVMQbJGA&url=http://farmfutures.com/story.aspx/biotechnology-spurs-talk-food-dialogues-17/65030

To Read More: Biotechnology Spurs Talk At Food Dialogues – Farm Futures
categoriaUncategorized commentoComments Off on Biotechnology Spurs Talk At Food Dialogues – Farm Futures | dataNovember 18th, 2012
Read All

Cultivator of Brain Parts

By Dr. Matthew Watson

Yoshiki Sasai is not just an ordinary tissue engineer who tries to coax stem cells to grow into fully formed bodily structures. It is true that Sasai has made his mark by taking on big projects like using stem cells to whip up a retina, cortical tissue and the cerebellum, involved with balance and movement. But his research has gone deeper by delving into the way stem cells organize themselves into complex structures under the influence of genes and the prenatal environment. Read a profile of Sasai here to accompany “ Grow Your Own Eye ,” Sasai’s own account of growing a retina in the November Scientific American .

[More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


Source:
http://rss.sciam.com/click.phdo?i=7291cadd43ac0cf30e9687431d559702

To Read More: Cultivator of Brain Parts
categoriaUncategorized commentoComments Off on Cultivator of Brain Parts | dataNovember 18th, 2012
Read All

How to Grow a Retina from Stem Cells (preview)

By Dr. Matthew Watson

In the womb, a ball of identical cells gives rise to varied cell types that ultimately form highly ordered structures and then the full panoply of organs in the human body. The process advances according to an internal biological script that directs each fold and crease of tissue to assume exactly the proper shape and dimension.

[More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


Source:
http://rss.sciam.com/click.phdo?i=1e6abdd024c3b29c15070219c99ad16a

To Read More: How to Grow a Retina from Stem Cells (preview)
categoriaUncategorized commentoComments Off on How to Grow a Retina from Stem Cells (preview) | dataNovember 18th, 2012
Read All

BioTime Will Have to Compete for California Cash for Geron’s Dormant Clinical Trial

By Dr. Matthew Watson


The California stem cell agency said
today it does not plan to reactivate the $25 million loan to assist
in Geron's spinal injury clinical trial despite an impending deal that would turn the effort over to BioTime, Inc.

Kevin McCormack, senior director for
public communications for the agency, said BioTime will have to
compete in an upcoming award round if it wants to win California
dollars.
Responding to a question from the
California Stem Cell Report, McCormack said,

“That (earlier) loan was specific to
Geron and when the trial was ended the loan ended too. Of course if
Biotime and Geron do complete their deal then Biotime would be free
to apply to us for a new disease team grant.”

McCormack later added that BioTime
could also compete in other appropriate rounds, including the
strategic partnership round just posted by CIRM. It provides for four
awards of up to $15 million. Funding could come as early as October
of next year. The strategic partnership round is a business-friendly
effort that is aimed at attracting “industry engagement and
investment.” The deadline for letters of intent is Dec. 18.
The stem cell agency made its $25
million loan to Geron in 2011 just a few months before the Menlo Park
firm abandoned its human embryonic stem cell trial for financial
reasons. (The full text of the loan agreement can be found here.) The company has repaid the loan with interest.
The company has tried to sell the
assets associated with the clinical trial since last November. The only public
interest that has surfaced has come from BioTime, Inc., of Alameda,
Ca. Michael West, founder of Geron, is the CEO of BioTime. Tom
Okarma
, CEO of Geron from 1999 to 2011, is CEO of the BioTime
subsidiary that would assume the clinical trial.
News from clinical trial is expected to
be published soon, according to a story in the San Francisco Business
Times
by Ron Leuty. He quoted CIRM President Alan Trounson as saying
that “some findings” from the trial would be published next month
in a medical journal.
Geron's stock traded at $1.24 at the
time of this writing today, up from $1.21 yesterday. BioTime's stock
stood at $2.99, up from $2.97.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/DS-6n2DoRy0/biotime-will-have-to-compete-for.html

To Read More: BioTime Will Have to Compete for California Cash for Geron’s Dormant Clinical Trial
categoriaStem Cell Therapy commentoComments Off on BioTime Will Have to Compete for California Cash for Geron’s Dormant Clinical Trial | dataNovember 18th, 2012
Read All

Geron, BioTime Deal Moves Forward with Letter of Intent

By Dr. Matthew Watson


Geron Corp., which once pioneered human
embryonic stem cell research, is close to selling off its hESC business in a complicated deal involving two former CEOs of the company and
BioTime, Inc., of Alameda, Ca.

The two publicly traded firms yesterday
announced a “letter of intent” involving a transaction in which
BioTime would acquire the assets of Geron's hESC clinical trial that
the company suddenly abandoned last year. The firm also laid off 66 people,
about 40 percent of its staff.
Abandonment of the program came only a
few months after the $3 billion California stem cell agency loaned Geron $25 million to assist in the trial. The agency could
restore the loan for the trial, but the Geron-BioTime announcement
did not mention that possibility. The California Stem Cell Report has
asked the agency for comment.
The letter of intent came one year and
one day after Geron announced that it was giving up the hESC spinal injury trial because of financial reasons. The Menlo Park, Ca., firm
has been trying to sell its hESC assets since then. BioTime has
been the only firm to express public interest. The Geron trial was
the first hESC trial approved by the FDA.
The proposed deal involves Michael
West
, who founded Geron and is now head of Biotime, and Tom Okarma,
who was CEO of Geron from 1999 to 2011. Okarma is now head of BioTime
Acquisition Corp.
,(BAC) a subsidiary of BioTime.
Here is how yesterday's press release
described the deal in which BioTime would acquire Geron's
“intellectual property and other assets related to Geron’s
discontinued human embryonic stem cell programs.”

“ BioTime would contribute
to BAC $5 million in cash, $30 million of BioTime common
shares, warrants to purchase eight (8) million common shares
of BioTime at a pre-specified price, rights to use certain
human embryonic stem cell lines, and minority stakes in two of
BioTime’s subsidiaries. In addition, a private investor would
invest $5 million in cash in BAC. 

“Following consummation of the
potential transaction, Geron stockholders would receive
shares representing 21.4% of the common stock of BAC as well as
warrants to purchase 8 million shares of BioTime common
stock at a pre-specified price. BioTime would own
approximately 71.6%, and a private investor would own approximately
7.0% of the outstanding BAC common stock for their $5
million investment. BioTime would also receive
warrants that would enable it to increase its ownership in BAC by
approximately 2%, which would reduce the Geron stockholders’
ownership in BAC to 19.2%. BAC would also be committed to pay
to Geron royalties on the sale of products that are
commercialized in reliance upon Geron patents acquired by
BAC.”

Prior to release of the letter of
intent, an article earlier this week by Vickie Brower in The Scientist said,

“The offer couldn’t come at a
better time for Geron, which in recent months has started to feel
pressure from its shareholders to boost its stock price and move
products through the pipeline. Since last November, when the company
announced its decision to shutter its hESC and regenerative medicine
business and funnel its resources into developing telomerase-related
treatments for cancer, the stock price has dropped more than 50
percent to $1.30 a share. Geron claimed the move was simply to save
money, but many took the decision—which effectively terminated a
clinical trial of an hESC treatment for spinal cord injury—as a
setback for the entire field." 

News coverage of yesterday's
announcement was light. Here is a link to a piece by Ryan McBride on
Fierce Biotech.

Geron's stock price closed at $1.21
yesterday and rose to $1.24 in after hours trading. BioTime closed at
$2.97. No after hours trading was reported for BioTime.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/b-E7JaABIOI/geron-biotime-deal-moves-forward-with.html

To Read More: Geron, BioTime Deal Moves Forward with Letter of Intent
categoriaStem Cell Therapy commentoComments Off on Geron, BioTime Deal Moves Forward with Letter of Intent | dataNovember 18th, 2012
Read All

Bone Marrow Stem cells for Rotator cuff Injury – Video

By raymumme


Bone Marrow Stem cells for Rotator cuff Injury
George Ramsey Describes the road to recovery of his shoulder function using his own bone marrow stemcellsFrom:FLRegenerativeMedViews:0 0ratingsTime:01:55More inEducation

Read the rest here:
Bone Marrow Stem cells for Rotator cuff Injury - Video

To Read More: Bone Marrow Stem cells for Rotator cuff Injury – Video
categoriaBone Marrow Stem Cells commentoComments Off on Bone Marrow Stem cells for Rotator cuff Injury – Video | dataNovember 17th, 2012
Read All

Stem Cell Therapy | Stem Cell Malaysia – Video

By daniellenierenberg


Stem Cell Therapy | Stem Cell Malaysia
stemcellmalaysia.com Stem cell therapy is a form of cell therapy that makes use of stem cells harvested from placenta for disease treatment. Stem cell therapy is also used for beauty, anti-aging and health rejuvenation purposes. The efficacy of stem cell therapy has been in practice for decades. Many rich and wealthy individuals and celebrities pay hefty price for stem cell therapy just to maintain youthfulness and vitality. For many severely ill-stricken people who have exhausted all means of conventional therapy look toward stem cell therapy for saving their condition and life. stemcellmalaysia.comFrom:stemcells2012Views:224 2ratingsTime:07:23More inHowto Style

Read the rest here:
Stem Cell Therapy | Stem Cell Malaysia - Video

To Read More: Stem Cell Therapy | Stem Cell Malaysia – Video
categoriaUncategorized commentoComments Off on Stem Cell Therapy | Stem Cell Malaysia – Video | dataNovember 17th, 2012
Read All

Mrs. Linda Flournoy – Video

By daniellenierenberg


Mrs. Linda Flournoy
describes ger experience with Stem Cell Therapy PRPFrom:FLRegenerativeMedViews:2 0ratingsTime:02:27More inEducation

Read more:
Mrs. Linda Flournoy - Video

To Read More: Mrs. Linda Flournoy – Video
categoriaUncategorized commentoComments Off on Mrs. Linda Flournoy – Video | dataNovember 17th, 2012
Read All

MS Journey – Adult Stem Cells Progress.wmv – Video

By daniellenierenberg


MS Journey - Adult Stem Cells Progress.wmv
Breif interview of my progress with Multiple Sclerosis with Adult Stem Cell therapy after my experience with Tysabri, Gilenya and Ampira..From:MSajourneyfromwithinViews:0 0ratingsTime:04:21More inEducation

See the original post here:
MS Journey - Adult Stem Cells Progress.wmv - Video

To Read More: MS Journey – Adult Stem Cells Progress.wmv – Video
categoriaUncategorized commentoComments Off on MS Journey – Adult Stem Cells Progress.wmv – Video | dataNovember 17th, 2012
Read All

The cell therapist

By LizaAVILA

For Dr. Robert Janson-Mller, the science of fresh cell therapy is in his blood.

His grandfather, Dr. Philipp Janson was one of the few doctors who introduced the treatment in Germany. His father, Dr. Wolfgang Janson-Mller continued the work that was eventually passed on to him.

He was exposed to the revolutionary world of fresh cell therapy early on in life. The treatment uses live young cells from a donor animal like sheep to help regenerate damaged cells in the body. Dr. Mller practically grew up in his grandfather and father's clinic where he met the former's patients, some of whom still go to him for their regular treatments.

''A child always wants to grow up like his father and do the same thing. My father left it open for me. He told me I could do whatever I want, the same thing I am doing now for my daughter. I'm also head of a clinic in Munich. This is what I do besides cell treatment. We have a family practice. That is my main job,'' shares the 46-year-old German doctor who recently visited the Philippines to acquaint Filipinos with the science of fresh cell therapy.

Dr. Mller, who owns a fresh cell therapy laboratory and works as head doctor of Med Activ clinic in Munich, says that despite the growing market for it in America and Asia, there are only five doctors in Germany practicing the science. The treatment is known to deter degenerative diseases such as arthrosis, rheumatism and neurological disorders such as multiple sclerosis. But it is most popular as an anti-aging treatment. Recently, it has also been used to treat children with autism and Down syndrome.

Yet, Dr. Mller points out that fresh cell therapy is not a miracle cure for aging or these diseases. Some bodies accept the treatment while some don't. And, it doesn't treat every disease known to mankind.

Nevertheless, patients from all over the world still flock to his private clinic at the Prinzregent Hotel in Edenkoben, Germany to avail themselves of the treatment, which does not come cheap. One session would cost about $12,000 or R624,000.

''I don't treat patients with cancer, tuberculosis, AIDS, or those who are pregnant. We don't treat patients with acute inflammations like appendicitis. Aside from that, I need to see if it makes sense. If I don't see a possibility, I say no,'' he explains.

In this 60 Minutes interview, Dr. Mller shares how fresh cell therapy really works and how it can take more than just one, two, 20, 60 or even 100 treatments to get it right. Some may start as young as eight months old or continue the treatment at 99 years old. This just proves that a patient is never too young nor too old for this revolutionary treatment. (Angelo G. Garcia)

STUDENTS AND CAMPUSES BULLETIN (SCB): A lot of people are confused about the difference between stem cell and fresh cell therapy.

Continue reading here:
The cell therapist

To Read More: The cell therapist
categoriaUncategorized commentoComments Off on The cell therapist | dataNovember 17th, 2012
Read All

Jill Helms, "Forever Young: The New Frontier of Stem Cell Medicine" – Video

By LizaAVILA


Jill Helms, "Forever Young: The New Frontier of Stem Cell Medicine"
The good part about getting older is that we gain some wisdom and patience. The bad part is that our bodies start to wear out. But what if we could revitalize our damaged bits back to a healthy state? Come hear what the field of Regenerative Medicine is striving to achieve, and learn how it all begins with the stem cell. Jill Helms is a professor in Plastic and Reconstructive Surgery in the department of surgery at Stanford University #39;s School of Medicine. This Classes Without Quizzes lecture was filmed on location at Stanford Reunion Homecoming 2012 by the Stanford Alumni Association.From:StanfordAlumniViews:11 0ratingsTime:54:05More inEducation

Follow this link:
Jill Helms, "Forever Young: The New Frontier of Stem Cell Medicine" - Video

To Read More: Jill Helms, "Forever Young: The New Frontier of Stem Cell Medicine" – Video
categoriaUncategorized commentoComments Off on Jill Helms, "Forever Young: The New Frontier of Stem Cell Medicine" – Video | dataNovember 15th, 2012
Read All

Page 630«..1020..629630631632..640650..»


Copyright :: 2025